Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Cefiderocol for treatment of complicated urinary tract infections.

Portsmouth S, Echols R, Den Nagata T.

Lancet Infect Dis. 2019 Jan;19(1):23-24. doi: 10.1016/S1473-3099(18)30721-7. No abstract available.

PMID:
30587290
2.

Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.

Portsmouth S, van Veenhuyzen D, Echols R, Machida M, Ferreira JCA, Ariyasu M, Tenke P, Nagata TD.

Lancet Infect Dis. 2018 Dec;18(12):1319-1328. doi: 10.1016/S1473-3099(18)30554-1. Epub 2018 Oct 25.

PMID:
30509675
3.

Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents.

Hayden FG, Sugaya N, Hirotsu N, Lee N, de Jong MD, Hurt AC, Ishida T, Sekino H, Yamada K, Portsmouth S, Kawaguchi K, Shishido T, Arai M, Tsuchiya K, Uehara T, Watanabe A; Baloxavir Marboxil Investigators Group.

N Engl J Med. 2018 Sep 6;379(10):913-923. doi: 10.1056/NEJMoa1716197.

4.

Safety and Efficacy of Pegylated Interferon Lambda, Ribavirin, and Daclatasvir in HCV and HIV-Coinfected Patients.

Nelson M, Rubio R, Lazzarin A, Romanova S, Luetkemeyer A, Conway B, Molina JM, Xu D, Srinivasan S, Portsmouth S.

J Interferon Cytokine Res. 2017 Mar;37(3):103-111. doi: 10.1089/jir.2016.0082. Epub 2017 Feb 17.

PMID:
28282271
5.

Peginterferon Lambda-1a/Ribavirin with Daclatasvir or Peginterferon Alfa-2a/Ribavirin with Telaprevir for Chronic Hepatitis C Genotype 1b.

Flisiak R, Kawazoe S, Znoyko O, Assy N, Gadano A, Kao JH, Lee KS, Zwirtes R, Portsmouth S, Dong Y, Xu D, Kumada H, Srinivasan S.

J Interferon Cytokine Res. 2016 Nov;36(11):635-643. Epub 2016 Jun 21.

PMID:
27327078
6.

A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3.

Foster GR, Chayama K, Chuang WL, Fainboim H, Farkkila M, Gadano A, Gaeta GB, Hézode C, Inada Y, Heo J, Kumada H, Lu SN, Marcellin P, Moreno C, Roberts SK, Strasser SI, Thompson AJ, Toyota J, Paik SW, Vierling JM, Zignego AL, Cohen D, McPhee F, Wind-Rotolo M, Srinivasan S, Hruska M, Myler H, Portsmouth SD.

Springerplus. 2016 Aug 19;5(1):1365. doi: 10.1186/s40064-016-2920-z. eCollection 2016.

7.

Five-year safety evaluation of maraviroc in HIV-1-infected treatment-experienced patients.

Gulick RM, Fatkenheuer G, Burnside R, Hardy WD, Nelson MR, Goodrich J, Mukwaya G, Portsmouth S, Heera JR.

J Acquir Immune Defic Syndr. 2014 Jan 1;65(1):78-81. doi: 10.1097/QAI.0b013e3182a7a97a.

8.

Genotypic analysis of the V3 region of HIV from virologic nonresponders to maraviroc-containing regimens reveals distinct patterns of failure.

Swenson LC, Chui CK, Brumme CJ, Chan D, Woods CK, Mo T, Dong W, Chapman D, Lewis M, Demarest JF, James I, Portsmouth S, Goodrich J, Heera J, Valdez H, Harrigan PR.

Antimicrob Agents Chemother. 2013 Dec;57(12):6122-30. doi: 10.1128/AAC.01534-13. Epub 2013 Sep 30.

9.

Safety and immunovirologic outcomes with maraviroc combination regimens in patients with a history of past treatment failures and virologic resistance in Brazil: an open-label, multicenter phase 3b study.

Furtado J, Madruga JV, Bicudo EL, da Eira M, Lopes MI, Netto EM, Santini-Oliveira M, Leite OH, Machado AA, Tupinambas U, de Andrade Neto JL, Lima MP, Pedro Rde J, Miranda AF, Lewi DS, Santos BR, Portsmouth S, Wajsbrot DB, Cassoli LM.

AIDS Res Hum Retroviruses. 2013 Sep;29(9):1203-10. doi: 10.1089/AID.2012.0330. Epub 2013 Jun 25.

PMID:
23731330
10.

Comparison of population and 454 "deep" sequence analysis for HIV type 1 tropism versus the original trofile assay in non-B subtypes.

Lee GQ, Harrigan PR, Dong W, Poon AF, Heera J, Demarest J, Rinehart A, Chapman D, Valdez H, Portsmouth S.

AIDS Res Hum Retroviruses. 2013 Jun;29(6):979-84. doi: 10.1089/AID.2012.0338. Epub 2013 Mar 6.

11.

Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot study.

Mills A, Mildvan D, Podzamczer D, Fätkenheuer G, Leal M, Than S, Valluri SR, Craig C, McFadyen L, Vourvahis M, Heera J, Valdez H, Rinehart AR, Portsmouth S.

J Acquir Immune Defic Syndr. 2013 Feb 1;62(2):164-70. doi: 10.1097/QAI.0b013e31827b51b5.

PMID:
23187936
12.

Correlation between genotypic (V3 population sequencing) and phenotypic (Trofile ES) methods of characterizing co-receptor usage of HIV-1 from 200 treatment-naïve HIV patients screened for Study A4001078.

Portsmouth S, Valluri SR, Däumer M, Thiele B, Valdez H, Lewis M, Craig C, Thielen A, James I, Demarest J, Heera J.

Antiviral Res. 2013 Jan;97(1):60-5. doi: 10.1016/j.antiviral.2012.11.002. Epub 2012 Nov 16.

PMID:
23165088
13.

Population-based sequencing of the V3-loop can predict the virological response to maraviroc in treatment-naive patients of the MERIT trial.

McGovern RA, Thielen A, Portsmouth S, Mo T, Dong W, Woods CK, Zhong X, Brumme CJ, Chapman D, Lewis M, James I, Heera J, Valdez H, Harrigan PR.

J Acquir Immune Defic Syndr. 2012 Nov 1;61(3):279-86. doi: 10.1097/QAI.0b013e31826249cf.

PMID:
23095934
14.

The epidemiology and clinical correlates of HIV-1 co-receptor tropism in non-subtype B infections from India, Uganda and South Africa.

Ataher Q, Portsmouth S, Napolitano LA, Eng S, Greenacre A, Kambugu A, Wood R, Badal-Faesen S, Tressler R.

J Int AIDS Soc. 2012 Jan 26;15(1):2. doi: 10.1186/1758-2652-15-2.

15.

Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: a reanalysis of the MERIT trial of maraviroc.

Swenson LC, Mo T, Dong WW, Zhong X, Woods CK, Thielen A, Jensen MA, Knapp DJ, Chapman D, Portsmouth S, Lewis M, James I, Heera J, Valdez H, Harrigan PR.

Clin Infect Dis. 2011 Oct;53(7):732-42. doi: 10.1093/cid/cir493.

PMID:
21890778
16.

The renaissance of fixed dose combinations: Combivir.

Portsmouth SD, Scott CJ.

Ther Clin Risk Manag. 2007 Aug;3(4):579-83.

17.

Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression?

Bansi LK, Benzie AA, Phillips AN, Portsmouth S, Hill T, Leen C, Schwenk A, Johnson M, Anderson J, Gilson R, Easterbrook P, Gazzard B, Fisher M, Orkin C, Porter K, Pillay D, Taylor GP, Walsh JC, Sabin CA; UK Collaborative HIV Cohort (UK CHIC) Study.

AIDS. 2008 Jan 30;22(3):349-56. doi: 10.1097/QAD.0b013e3282f4709a.

PMID:
18195561
18.

Infant HIV infection despite "universal" antenatal testing.

Struik SS, Tudor-Williams G, Taylor GP, Portsmouth SD, Foster CJ, Walsh C, Hanley C, Walters S, Smith JH, Lyall H.

Arch Dis Child. 2008 Jan;93(1):59-61. Epub 2007 Sep 12.

PMID:
17855439
19.

Are disulfiram-like reactions associated with abacavir-containing antiretroviral regimens in clinical practice?

Barber TJ, Marett B, Waldron S, Portsmouth S, Mackie NE, Weston R, Winston A.

AIDS. 2007 Aug 20;21(13):1823-4.

PMID:
17690585
20.

Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failures.

Benzie AA, Bansi LK, Sabin CA, Portsmouth S, Hill T, Johnson M, Gilson R, Easterbrook P, Gazzard B, Fisher M, Orkin C, Dunn D, Delpech V, Taylor GP, Walsh JC, Phillips AN; United Kingdom Collaborative HIV Cohort (CHIC) Study Group.

AIDS. 2007 Jul 11;21(11):1423-30.

PMID:
17589188
21.

The first point prevalence study of genital Chlamydia trachomatis infection in young male inmates in the UK.

Menon-Johansson AS, Winston A, Matthews G, Portsmouth S, Daniels D.

Int J STD AIDS. 2005 Dec;16(12):799-801.

PMID:
16336761
23.

Studies on the allostimulatory function of dendritic cells from HCV-HIV-1 co-infected patients.

Stebbing J, Patterson S, Portsmouth S, Thomas C, Glassman R, Wildfire A, Gotch F, Bower M, Nelson M, Gazzard B.

Cell Res. 2004 Jun;14(3):251-6.

24.

A questionnaire survey of stress and bullying in doctors undertaking research.

Stebbing J, Mandalia S, Portsmouth S, Leonard P, Crane J, Bower M, Earl H, Quine L.

Postgrad Med J. 2004 Feb;80(940):93-6.

25.

Treatment of primary HIV-1 infection with nonnucleoside reverse transcriptase inhibitor-based therapy is effective and well tolerated.

Portsmouth S, Imami N, Pires A, Stebbing J, Hand J, Nelson M, Gotch F, Gazzard BG.

HIV Med. 2004 Jan;5(1):26-9.

26.

The efficacy of ritonavir in the prevention of AIDS-related Kaposi's sarcoma.

Stebbing J, Portsmouth S, Nelson M, Mandalia S, Kandil H, Alexander N, Davies L, Brock C, Bower M, Gazzard B.

Int J Cancer. 2004 Feb 10;108(4):631-3.

27.

HIV and AIDS in the People's Republic of China: a collaborative review.

Portsmouth S, Stebbing J, Keyi X, Jianping Z, Guohua P.

Int J STD AIDS. 2003 Nov;14(11):757-61. Review.

PMID:
14624739
28.

Innate and adaptive immunological insights into HIV pathogenesis.

Kandil H, Stebbing J, Gazzard B, Portsmouth S.

Int J STD AIDS. 2003 Oct;14(10):652-5. Review.

PMID:
14596766
29.

Paclitaxel for anthracycline-resistant AIDS-related Kaposi's sarcoma: clinical and angiogenic correlations.

Stebbing J, Wildfire A, Portsmouth S, Powles T, Thirlwell C, Hewitt P, Nelson M, Patterson S, Mandalia S, Gotch F, Gazzard BG, Bower M.

Ann Oncol. 2003 Nov;14(11):1660-6.

PMID:
14581275
30.

Multiple human papillomavirus types appear to be a feature of anal not cervical intra-epithelial neoplasia.

Stebbing J, Portsmouth S, Fox P, Brock C, Bower M.

AIDS. 2003 Nov 7;17(16):2401. No abstract available.

PMID:
14571196
31.

Current treatment of HIV infection.

Portsmouth S, Stebbing J, Gazzard B.

Curr Top Med Chem. 2003;3(13):1458-66. Review.

PMID:
14529521
32.

A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma.

Portsmouth S, Stebbing J, Gill J, Mandalia S, Bower M, Nelson M, Bower M, Gazzard B.

AIDS. 2003 Jul 25;17(11):F17-22.

PMID:
12853764
33.

Insights into the molecular biology and sero-epidemiology of Kaposi's sarcoma.

Stebbing J, Portsmouth S, Bower M.

Curr Opin Infect Dis. 2003 Feb;16(1):25-31. Review.

PMID:
12821826
34.

Disease-associated dendritic cells respond to disease-specific antigens through the common heat shock protein receptor.

Stebbing J, Gazzard B, Portsmouth S, Gotch F, Kim L, Bower M, Mandalia S, Binder R, Srivastava P, Patterson S.

Blood. 2003 Sep 1;102(5):1806-14. Epub 2003 May 15.

35.

Kaposi's sarcoma--an update.

Stebbing J, Portsmouth S, Gotch F, Gazzard B.

Int J STD AIDS. 2003 Apr;14(4):225-7. Review. No abstract available.

PMID:
12716490
36.

Prospective cohort study showing changes in the monthly incidence of Pneumocystis carinii pneumonia.

Lubis N, Baylis D, Short A, Stebbing J, Teague A, Portsmouth S, Bower M, Nelson M, Gazzard B.

Postgrad Med J. 2003 Mar;79(929):164-6.

37.

How does HAART lead to the resolution of Kaposi's sarcoma?

Stebbing J, Portsmouth S, Gazzard B.

J Antimicrob Chemother. 2003 May;51(5):1095-8. Epub 2003 Mar 28. Review. No abstract available.

PMID:
12668573
38.

Lack of response of anal intra-epithelial neoplasia to highly active antiretroviral therapy.

Fox P, Stebbing J, Portsmouth S, Winston A, Frances N, Nelson M, Gazzard B, Bower M.

AIDS. 2003 Jan 24;17(2):279-80. No abstract available.

PMID:
12545098
39.

The heat-shock protein receptor CD91 is up-regulated in monocytes of HIV-1-infected "true" long-term nonprogressors.

Stebbing J, Gazzard B, Kim L, Portsmouth S, Wildfire A, Teo I, Nelson M, Bower M, Gotch F, Shaunak S, Srivastava P, Patterson S.

Blood. 2003 May 15;101(10):4000-4. Epub 2003 Jan 16.

40.

An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals.

Nelson M, Portsmouth S, Stebbing J, Atkins M, Barr A, Matthews G, Pillay D, Fisher M, Bower M, Gazzard B.

AIDS. 2003 Jan 3;17(1):F7-10.

PMID:
12478090
41.

The immunological effects of concomitant highly active antiretroviral therapy and liposomal anthracycline treatment of HIV-1-associated Kaposi's sarcoma.

Esdaile B, Davis M, Portsmouth S, Sarker D, Nelson M, Gazzard B, Bower M.

AIDS. 2002 Nov 22;16(17):2344-7.

PMID:
12441811
42.

TV or not TV?

Smith A, Portsmouth S, Curran B, Warhurst D, Kell P, Saulsbury N.

Sex Transm Infect. 2002 Jun;78(3):185-6. No abstract available.

43.
44.

Management of prisoners with HIV infection. Real commitment to prevention is needed.

Portsmouth S.

BMJ. 2001 Jul 28;323(7306):231. No abstract available.

PMID:
11496878
45.

Etiology and natural history of neutropenia in human immunodeficiency virus disease: a prospective study.

Moore DA, Benepal T, Portsmouth S, Gill J, Gazzard BG.

Clin Infect Dis. 2001 Feb 1;32(3):469-75. Epub 2001 Jan 23.

PMID:
11170956

Supplemental Content

Loading ...
Support Center